Medicenna Therapeutics (TSE:MDNA) Sets New 12-Month Low – Here’s What Happened

Medicenna Therapeutics Corp. (TSE:MDNA)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$0.60 and last traded at C$0.64, with a volume of 21093 shares trading hands. The stock had previously closed at C$0.61.

Medicenna Therapeutics Stock Up 4.9%

The company has a 50-day moving average of C$0.79 and a 200-day moving average of C$1.03. The company has a market capitalization of C$53.39 million, a price-to-earnings ratio of -4.27 and a beta of 2.84. The company has a current ratio of 2.68, a quick ratio of 4.65 and a debt-to-equity ratio of 3.30.

Medicenna Therapeutics (TSE:MDNA) last announced its quarterly earnings data on Friday, February 13th. The company reported C($0.05) earnings per share for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 103.51%. On average, equities analysts predict that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current fiscal year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.